vs
HELEN OF TROY LTD（HELE）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是HELEN OF TROY LTD的1.2倍（$622.0M vs $512.8M），Royalty Pharma plc净利率更高（34.4% vs -16.4%，领先50.8%），Royalty Pharma plc同比增速更快（4.8% vs -3.4%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.4%）
海伦特洛伊是美国上市企业，主营自有及授权品牌家居用品、健康家居用品与美容产品的设计研发和全球营销，旗下拥有OXO International、Kaz等多家子公司。公司注册总部设于百慕大汉密尔顿，美国运营总部位于得克萨斯州埃尔帕索，公司名称源自古希腊神话人物特洛伊海伦。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
HELE vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.2倍
$512.8M
营收增速更快
RPRX
高出8.1%
-3.4%
净利率更高
RPRX
高出50.8%
-16.4%
两年增速更快
RPRX
近两年复合增速
2.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $512.8M | $622.0M |
| 净利润 | $-84.1M | $214.2M |
| 毛利率 | 46.9% | — |
| 营业利润率 | -1.6% | 62.4% |
| 净利率 | -16.4% | 34.4% |
| 营收同比 | -3.4% | 4.8% |
| 净利润同比 | -269.4% | 2.9% |
| 每股收益（稀释后） | $-3.65 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HELERPRX
| Q4 25 | $512.8M | $622.0M | ||
| Q3 25 | $431.8M | $609.3M | ||
| Q2 25 | $371.7M | $578.7M | ||
| Q1 25 | $485.9M | $568.2M | ||
| Q4 24 | $530.7M | $593.6M | ||
| Q3 24 | $474.2M | $564.7M | ||
| Q2 24 | $416.8M | $537.3M | ||
| Q1 24 | $489.2M | $568.0M |
净利润HELERPRX
| Q4 25 | $-84.1M | $214.2M | ||
| Q3 25 | $-308.6M | $288.2M | ||
| Q2 25 | $-450.7M | $30.2M | ||
| Q1 25 | $50.9M | $238.3M | ||
| Q4 24 | $49.6M | $208.2M | ||
| Q3 24 | $17.0M | $544.0M | ||
| Q2 24 | $6.2M | $102.0M | ||
| Q1 24 | $42.7M | $4.8M |
毛利率HELERPRX
| Q4 25 | 46.9% | — | ||
| Q3 25 | 44.2% | — | ||
| Q2 25 | 47.1% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 48.9% | — | ||
| Q3 24 | 45.6% | — | ||
| Q2 24 | 48.7% | — | ||
| Q1 24 | 49.0% | — |
营业利润率HELERPRX
| Q4 25 | -1.6% | 62.4% | ||
| Q3 25 | -73.1% | 70.1% | ||
| Q2 25 | -109.5% | 36.3% | ||
| Q1 25 | 0.4% | 94.0% | ||
| Q4 24 | 14.2% | 60.9% | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 7.4% | 50.2% | ||
| Q1 24 | 13.5% | -13.0% |
净利率HELERPRX
| Q4 25 | -16.4% | 34.4% | ||
| Q3 25 | -71.5% | 47.3% | ||
| Q2 25 | -121.3% | 5.2% | ||
| Q1 25 | 10.5% | 41.9% | ||
| Q4 24 | 9.3% | 35.1% | ||
| Q3 24 | 3.6% | 96.3% | ||
| Q2 24 | 1.5% | 19.0% | ||
| Q1 24 | 8.7% | 0.8% |
每股收益（稀释后）HELERPRX
| Q4 25 | $-3.65 | $0.49 | ||
| Q3 25 | $-13.44 | $0.67 | ||
| Q2 25 | $-19.65 | $0.07 | ||
| Q1 25 | $2.20 | $0.55 | ||
| Q4 24 | $2.17 | $0.46 | ||
| Q3 24 | $0.74 | $1.21 | ||
| Q2 24 | $0.26 | $0.23 | ||
| Q1 24 | $1.76 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $852.3M | $9.7B |
| 总资产 | $2.3B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资HELERPRX
| Q4 25 | $27.1M | $618.7M | ||
| Q3 25 | $22.4M | $938.9M | ||
| Q2 25 | $22.7M | $631.9M | ||
| Q1 25 | $18.9M | $1.1B | ||
| Q4 24 | $40.8M | $929.0M | ||
| Q3 24 | $20.1M | $950.1M | ||
| Q2 24 | $16.1M | $1.8B | ||
| Q1 24 | $18.5M | $843.0M |
总债务HELERPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | $921.9M | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | $672.0M | $6.1B |
股东权益HELERPRX
| Q4 25 | $852.3M | $9.7B | ||
| Q3 25 | $926.3M | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.7B | $9.8B | ||
| Q4 24 | $1.6B | $10.3B | ||
| Q3 24 | $1.6B | $10.3B | ||
| Q2 24 | $1.5B | $9.8B | ||
| Q1 24 | $1.6B | $9.9B |
总资产HELERPRX
| Q4 25 | $2.3B | $19.6B | ||
| Q3 25 | $2.4B | $19.3B | ||
| Q2 25 | $2.7B | $18.3B | ||
| Q1 25 | $3.1B | $17.6B | ||
| Q4 24 | $3.0B | $18.2B | ||
| Q3 24 | $2.9B | $18.0B | ||
| Q2 24 | $2.8B | $17.7B | ||
| Q1 24 | $2.8B | $16.1B |
负债/权益比HELERPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | 0.55× | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | 0.41× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $5.8M | — |
| 自由现金流率自由现金流/营收 | 1.1% | — |
| 资本支出强度资本支出/营收 | 1.2% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $55.9M | — |
8季度趋势，按日历期对齐
经营现金流HELERPRX
| Q4 25 | $11.9M | $827.1M | ||
| Q3 25 | $-10.5M | $702.6M | ||
| Q2 25 | $58.3M | $364.0M | ||
| Q1 25 | $35.0M | $596.1M | ||
| Q4 24 | $8.3M | $742.5M | ||
| Q3 24 | $44.6M | $703.6M | ||
| Q2 24 | $25.3M | $658.2M | ||
| Q1 24 | $73.6M | $664.6M |
自由现金流HELERPRX
| Q4 25 | $5.8M | — | ||
| Q3 25 | $-21.9M | — | ||
| Q2 25 | $45.0M | — | ||
| Q1 25 | $27.1M | — | ||
| Q4 24 | $191.0K | — | ||
| Q3 24 | $39.7M | — | ||
| Q2 24 | $16.2M | — | ||
| Q1 24 | $66.6M | — |
自由现金流率HELERPRX
| Q4 25 | 1.1% | — | ||
| Q3 25 | -5.1% | — | ||
| Q2 25 | 12.1% | — | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 8.4% | — | ||
| Q2 24 | 3.9% | — | ||
| Q1 24 | 13.6% | — |
资本支出强度HELERPRX
| Q4 25 | 1.2% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 1.4% | — |
现金转化率HELERPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 0.69× | 2.50× | ||
| Q4 24 | 0.17× | 3.57× | ||
| Q3 24 | 2.62× | 1.29× | ||
| Q2 24 | 4.08× | 6.45× | ||
| Q1 24 | 1.72× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HELE
| Beauty Wellness | $283.2M | 55% |
| Home Outdoor | $229.6M | 45% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
